Advertisement
Screener

Amylyx Pharmaceuticals, Inc. (AMLX) Material Contracts

Amylyx Pharmaceuticals, Inc. Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

  • 2026-03-03: Form 10-K; Exhibit 10.3; Description Amended and Restated Non-Employee Director Compensation Policy.
  • 2025-05-08: Form 10-Q; Exhibit 10.1; Description Form of Performance-Based Restricted Stock Unit Award Agreement for Company Employees under the Amylyx Pharmaceuticals, Inc. 2022 Stock Option and Incentive Plan..
  • 2025-03-04: Form 10-K; Exhibit 10.11; Description Form of Employment Agreement, between the Registrant and Camille Bedrosian..
  • 2024-06-21: Form 8-K; Exhibit 10.1; Description Asset Purchase Agreement, dated June 21, 2024.*.
FiledFormExhibitDescription
2026-03-0310-K10.3Amended and Restated Non-Employee Director Compensation Policy
2025-05-0810-Q10.1Form of Performance-Based Restricted Stock Unit Award Agreement for Company Employees under the Amylyx Pharmaceuticals, Inc. 2022 Stock Option and Incentive Plan.
2025-03-0410-K10.11Form of Employment Agreement, between the Registrant and Camille Bedrosian.
2024-06-218-K10.1Asset Purchase Agreement, dated June 21, 2024.*
2024-05-0910-Q10.1Amended and Restated Non-Employee Director Compensation Policy.
2024-02-2210-K10.17Separation Agreement between Registrant and Margaret Olinger dated December 31, 2023.
2024-02-2210-K10.15Form of Employment Agreement, between the Registrant and Camille Bedrosian.
2024-02-2210-K10.13Amendment to Employment Agreement, effective as of November 27, 2023, by and between the Company and Patrick Yeramian.
2023-08-1010-Q10.1Commercial Supply Agreement, dated as of August 8, 2023, by and between the Registrant and ICE S.p.A. (formerly Prodotti Chimici e Alimentari S.p.A.).
2023-05-1110-Q10.4First Amendment, effective as of January 1, 2023, to the Supply Agreement, dated as of October 29, 2019, by and between the Registrant and CU Chemie Uetikon GmbH.
2023-05-1110-Q10.3Second Amendment, dated as of March 20, 2023, to Product Agreement, dated as of November 12, 2019, as amended by Amendment No. 1, dated as of January 18, 2021, pursuant to the Master Manufacturing Services Agreement, dated as of November 12, 2019, by and between the Registrant and Patheon Inc.
2023-05-1110-Q10.2First Amendment, dated as of January 18, 2021, to Product Agreement, dated as of November 12, 2019, pursuant to the Master Manufacturing Services Agreement, dated as of November 12, 2019, by and between the Registrant and Patheon Inc.
2023-03-218-K10.1Non-Employee Director Compensation Policy
2023-03-1310-K10.18Form of Employment Agreement, between the Registrant and Gina Mazzariello
2022-12-068-K10.1Amendment to Employment Agreement, effective as of December 1, 2022, by and between the Company and Patrick Yeramian.

Similar stocks

Stock NameCountryMarket CapPE Ratio
Enliven Therapeutics, Inc. (ELVN)United States$3.307B-35.07
Arcutis Biotherapeutics, Inc. (ARQT)United States$3.303B115.47
Arcus Biosciences, Inc. (RCUS)United States$3.188B-8.52
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Organon & Co. (OGN)United States$3.603B17.03
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27
ACADIA PHARMACEUTICALS INC (ACAD)United States$3.823B11.45
AbCellera Biologics Inc. (ABCL)$3.879B-14.59
PRECIGEN, INC. (PGEN)United States$2.757B-12.94